CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Cash flows from operating activities:
Net loss	$ (95,960)	$ (132,442)	$ (94,989)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	4,156	2,584	1,041
Non-cash lease expense	1,402	1,249	415
(Gain) loss on marketable securities, net	(5,587)	20,603	5,023
Loss on disposal of fixed assets	136	91	70
Goodwill impairment	0	9,483	0
Change in fair value of warrant liabilities	278	(6,243)	(4,379)
Change in fair value of contingent consideration	(400)	176	36
Change in fair value of stock consideration	0	(320)	0
Stock-based compensation	8,516	11,206	24,918
Changes in operating assets and liabilities:
Accounts receivable, net	(368)	0	0
Inventory, net	(3,096)	0	0
Prepaid expenses and other current assets	2,159	(1,005)	(4,893)
Operating lease right-of-use assets	(83)	(10,033)	(7,388)
Other assets	2	(7)	(690)
Other assets - related party	0	0	738
Accounts payable	(1,220)	721	709
Accrued expenses and other current liabilities	(1,835)	4,009	4,498
Other long-term liabilities	7	0	0
Operating lease liabilities	(2,143)	9,368	8,078
Net cash used in operating activities	(94,036)	(90,560)	(66,813)
Cash flows from investing activities:
Purchases of property and equipment	(4,510)	(10,741)	(5,763)
Internally developed software - capitalized costs	(763)	0	0
Purchases of marketable securities	(123,809)	(834)	(440,542)
Sales of marketable securities	272,510	148,760	0
Business acquisition	0	0	(4,632)
Net cash provided by (used in) investing activities	143,428	137,185	(450,937)
Cash flows from financing activities:
Proceeds from exercise of stock options	357	2,757	5,618
Deferred offering costs	(208)	0	0
Net proceeds from equity infusion from the Business Combination	0	0	512,788
Payment of notes payable	0	0	(1,749)
Stock issuance costs for Series E convertible preferred stock	0	0	(4)
Payment of contingent consideration - business acquisition	0	(348)	0
Payment of deferred consideration - business acquisition	0	(500)	0
Principal payments under finance lease obligations	0	0	(28)
Net cash provided by financing activities	149	1,909	516,625
Net increase (decrease) in cash and cash equivalents	49,541	48,534	(1,125)
Cash and cash equivalents at beginning of period	84,319	35,785	36,910
Cash and cash equivalents at end of period	133,860	84,319	35,785
Supplemental disclosure of cash flow information:
Cash received from exchange of research and development tax credits	1,523	0	173
Supplemental disclosure of non-cash investing and financing activities:
Property and equipment purchased but not paid	302	1,260	1,385
Deferred offering costs payable	105	0	0
Forgiveness of related party promissory notes	0	0	150
Noncash equity issuance - business acquisition	0	151	4,232
Noncash equity related warrants from the Business Combination	0	0	11,618
Conversion of the convertible preferred stock into Class A and Class B common stock	0	0	195,810
Noncash contingent consideration and holdbacks - business acquisition	$ 0	$ 0	$ 1,552